Visipaque

Visipaque®

Iodixanol Imaging A nonionic radiocontrast Indications Intraarterial–eg, visceral intraarterial digital subtraction angiography, angiocardiography–eg, left ventriculography and selective coronary arteriography, peripheral arteriography, visceral arteriography, cerebral arteriography; IV injection for CECT–contrast-enhanced CT imaging of head and body, excretory urography, peripheral venography. See Radiocontract.
Mentioned in ?
References in periodicals archive ?
Tenders are invited for Visipaque 270 mg i ml 50 ml iodixanol plus pack usfda ce mark approved
For the second CBCT, after placing a 5 F catheter in the common or proper hepatic artery, the contrast medium (Visipaque 270, GE Healthcare) was injected using a power injector at a rate of 1.5 or 2 mL/s for 12 s (for a total of 18 or 24 mL) and image acquisition was performed after an 8 s delay.
The late arterial phase was acquired using an intravenous injection of 80 cc Visipaque 320 (GE Healthcare, Waukesha, WI) at a rate of 4 cc/second with a power injector.
Multiphase imaging of the abdomen was performed by intravenous application of 80-150 mL of nonionic contrast agent (Iomeron, iodine concentration 400 mg/mL; Ultravist, iodine concentration 370 mg/mL; or Visipaque, iodine concentration 320 mg/mL) in bolus through venous cannulas, size 18-20 gauge.
Although the literature is not conclusive, it suggests that the isoosmolar contrast agent Visipaque may be associated with lower rates of CI-AKI when compared with omnipaque, especially in patients with CKD and in those with CKD and diabetes mellitus (Basu, 2017).
A total of 248 ml of iodixanol (Visipaque) containing 320 mg-iodine/ml intra-arterial injection was administered for aortic arch and thoracic aortic arteriogram to evaluate anatomy and blood flow and for endoleak assessment.
The drug concentrations of 4 vol%, 10 vol% and 20 vol% of iodixanol (Visipaque 320 mg I/mL) and iohexol (Omnipaque 300 mg I/mL) were used, in an attempt to approximate the relative concentrations of contrast media in blood that might occur during the bolus-injection and circulation-diluted phases of drug administration.
Contrast agent used was Visipaque at a dose of 1 mL/kg body weight, injected through the median cubital vein with a rate of 4.7-5 mL/s.
Iodixanol (VISIPAQUE, GE Healthcare, Cork, Ireland) with an iodine concentration of 320 mg I/mL was used as the standard of care contrast media.
We hypothesized that this sample was contaminated with Visipaque (3), a contrast medium used in computed tomography--guided SVS that can increase plasma density (4).
Giles, UK: GE Healthcare today announced results from an independent study, which showed that use of isosmolar contrast agent Visipaque 320 (iodixanol 320mg I/ml) provides better image quality of coronary stents during multi-detector CT coronary angiography (MDCT-CA) than use of Iomeron 400 (iomeprol 400mg l/ml) when injected at the same flow rate (5.0 ml/s) and volume (80ml).
(2) Cerebrospinal fluid was visibly present in the spinal needle before contrast medium (Visipaque 270 mg/ mL, GE Health Care AG, Wadenswil, Switzerland) was injected.